LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Celldex today and set a price target of $61.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sam Slutsky has given his Buy rating due to a combination of factors that highlight Celldex’s promising clinical development pipeline. The company is advancing its Phase 3 program for barzolvolimab, targeting chronic spontaneous urticaria, with enrollment expected to complete by Summer 2026. Additionally, Celldex plans to initiate a long-term extension study for patients completing the ongoing trials, which could further validate the efficacy of barzolvolimab.
Moreover, Celldex is preparing for initial Phase 2 data in the second half of 2026 for barzolvolimab in prurigo nodularis and atopic dermatitis, with prior trials indicating potential efficacy. The company is also set to begin a Phase 3 program for cold urticaria and symptomatic dermographism by December 2025, following promising Phase 2 data. These developments, alongside the expected data from the Phase 1 study of CDX-622, position Celldex as a strong candidate for growth, justifying the Buy rating.